- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.04. | Pharmaceutical compliance management software for the pharmaceutical industry | ||
| 19.04. | NIH team develops AI tool to predict cancer drug response | ||
| 19.04. | FDA approves Takeda's ENTYVIO SC for Crohn's disease | ||
| 19.04. | The next phase for mRNA: Looking beyond COVID-19 | ||
| 19.04. | Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval | ||
| 19.04. | SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval | ||
| 19.04. | SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma: Likelihood of Approval | ||
| 19.04. | SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval | ||
| 19.04. | SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: Likelihood of Approval | ||
| 19.04. | SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Melanoma: Likelihood of Approval | ||
| 19.04. | SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Likelihood of Approval | ||
| 18.04. | Weekly insulin analogues approaching approval could herald change | ||
| 18.04. | "Lack of harmonisation in Europe" hindering gene therapy growth | ||
| 18.04. | Chemomab touts study confirming CCL24 link to systemic sclerosis severity | ||
| 18.04. | OncoX inks licensing deal worth over $26m for NSCLC therapy | ||
| 18.04. | Inflammation among current dementia research focus, says Alchemab CSO | ||
| 18.04. | Comprehensive clinical trial services | ||
| 18.04. | Outrun Therapeutics announces launch with $10m seed funding | ||
| 18.04. | Clearmind licenses psychedelic compounds for mental disorders | ||
| 18.04. | The importance of finding a versatile, scalable CDMO in the softgel market | ||
| 18.04. | The importance of AI in protecting hospitals from cyberattacks | ||
| 18.04. | Theolytics secures funds to advance oncolytic adenovirus therapy | ||
| 18.04. | Essential Pharma acquires Reminyl from Janssen Pharmaceutica | ||
| 18.04. | Everolimus by Novartis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval | ||
| 18.04. | Everolimus by Novartis for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
